Alzheimers & Dementia 投稿命中率-刊鹿论文编译

PROFILE OF AND RISK FACTORS FOR POST-STROKE COGNITIVE IMPAIRMENT IN DIVERSE ETHNO-REGIONAL GROUPS

Abstract:

Objective To address the variability in prevalence estimates and inconsistencies in potential risk factors for poststroke cognitive impairment (PSCI) using a standardized approach and individual participant data (IPD) from international cohorts in the Stroke and Cognition Consortium (STROKOG) consortium. Methods We harmonized data from 13 studies based in 8 countries. Neuropsychological test scores 2 to 6 months after stroke or TIA and appropriate normative data were used to calculate standardized cognitive domain scores. Domain-specific impairment was based on percentile cutoffs from normative groups, and associations between domain scores and risk factors were examined with 1-stage IPD meta-analysis. Results In a combined sample of 3,146 participants admitted to hospital for stroke (97%) or TIA (3%), 44% were impaired in global cognition and 30% to 35% were impaired in individual domains 2 to 6 months after the index event. Diabetes mellitus and a history of stroke were strongly associated with poorer cognitive function after covariate adjustments; hypertension, smoking, and atrial fibrillation had weaker domain-specific associations. While there were no significant differences in domain impairment among ethnoracial groups, some interethnic differences were found in the effects of risk factors on cognition. Conclusions This study confirms the high prevalence of PSCI in diverse populations, highlights common risk factors, in particular diabetes mellitus, and points to ethnoracial differences that warrant attention in the development of prevention strategies. From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht,MaastrichtUniversityMedicalCenter, theNetherlands;MemoryAgingandCognitionCentre (C.C., X.X., E.J.C.),DepartmentofPharmacology, YongLooLinSchoolofMedicine,National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUSMedical School (N.K.), Singapore; Dementia Collaborative ResearchCentre (H.B., P.S.S.), University of NewSouthWales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France. Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. STROKOG collaboration coinvestigators are listed in Appendix 2 at the end of the article. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. e2257 While poststroke cognitive impairment (PSCI) is mild in many stroke survivors, numerous studies have reported a prevalence of dementia in poststroke cases that varies from 7.4% in a population-based study of first stroke to 41.3% in hospital-based cases of recurrent stroke. The prevalence may differ by geographic region, diagnostic criteria, and methods of assessment. Because the severity of cognitive impairment in poststroke patients is on a continuum, however, it is arguably more meaningful to use a standardized continuous measure to examine cognitive impairment rather than the diagnosis of dementia. Because of the heterogeneity of stroke and its effects on cerebral function, the cognitive profile of poststroke dementia is understandably complex. There is evidence that some cognitive domains, in particular complex attention, working memory, and frontal executive function, are affected early in vascular dementia. Poststroke dementia, however, is also associated with language and visuospatial dysfunction, even though individuals with severe language impairment are often excluded from detailed investigations. In addition, studies of cognitive profile have largely been conducted in white, non-Hispanic populations, and it is uncertain whether the same pattern is seen in Asian and African populations. The clinical determinants of PSCI remain incompletely understood. While older age and low levels of education have consistently emerged as risk factors, various other putative risk factors have been inconsistently reported, including risk factors for cerebrovascular disease (e.g., hypertension, diabetes mellitus, atrial fibrillation [AF], smoking), prior pathology (e.g., previous stroke, Alzheimer disease), APOE genotype, stroke features, and lesion characteristics. The variability of the findings has prevented a consensus from being reached on the most relevant factors in predicting the development of poststroke dementia. The Stroke and Cognition Consortium (STROKOG), an international consortium of studies of cognitive decline and dementia after stroke or TIA, offers an opportunity to address the inconsistencies in prevalence estimates and potential risk factors for PSCI. This article presents a comprehensive profile of the cognitive performance of patients 2 to 6 months after stroke or TIA and explores the associations between a variety of risk factors and impairment in cognitive function. We hypothesized that the prevalence of Glossary AF = atrial fibrillation; CHF = congestive heart failure; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, 4th edition; IPD = individual participant data; MI = myocardial infarction; NEMESIS = North East Melbourne Stroke Incidence Study; PROSPER = Prospective Study of Pravastatin in the Elderly at Risk; PSCI = poststroke cognitive impairment; SAM = Helsinki Stroke Aging Memory Study; STROKDEM = Study of Factors Influencing Post-Stroke Dementia; STROKOG = Stroke and Cognition Consortium. e2258 Neurology | Volume 93, Number 24 | December 10, 2019 Neurology.org/N PSCI will be high across different geographical regions but will vary across different ethnoracial groups. We also hypothesized that PSCI affects different cognitive domains equally and that vascular risk factors for stroke are also risk factors for PSCI independently of the occurrence of stroke.

Author Listing： Jessica W. Lo;John D. Crawford;David W. Desmond;Olivier Godefroy;Perminder S. Sachdev

Volume： 15

Pages： None

DOI： 10.1016/j.jalz.2019.06.4755

Language： English

Journal： Alzheimer s & Dementia

Alzheimers & Dementia

ALZHEIMERS DEMENT

影响因子：13.0

是否综述期刊：是

是否OA：否

是否预警：不在预警名单内

发行时间：2005

ISSN：1552-5260

发刊频率：Quarterly

收录数据库：SCIE/Scopus收录

出版国家/地区：UNITED STATES

出版社：Elsevier Inc.

期刊介绍

The mission of Alzheimer & Dementia: Journal of the Alzheimer Association is to bridge the knowledge gaps across a wide range of bench-to-bedside investigation. The journal publishes the results of studies in: behavior, biochemistry, genetics, molecular biology, pharmacology, physiology, protein chemistry, neurology, neuropathology, psychiatry, geriatrics, neuropsychology, epidemiology, sociology, health services research, health economics, political science and public policy. Content emphasizes interdisciplinary investigations, integrative/translational articles, related to: etiology, risk factors, early detection, disease modifying interventions, prevention of dementia and applications of new technologies in health services.

阿尔茨海默病和痴呆症的使命：阿尔茨海默氏症协会杂志是桥梁的知识差距跨越广泛的实验室到床边的调查。该杂志发表的研究结果：行为学、生物化学、遗传学、分子生物学、药理学、生理学、蛋白质化学、神经学、神经病理学、精神病学、老年病学、神经心理学、流行病学、社会学、卫生服务研究、卫生经济学、政治学和公共政策。内容强调跨学科研究、综合/转化文章，涉及：病因学、危险因素、早期发现、疾病改善干预、预防痴呆症和新技术在保健服务中的应用。

年发文量	459
国人发稿量	63
国人发文占比	13.73%
自引率	7.7%
平均录取率	很难
平均审稿周期	较慢,6-12周平均6.5周
版面费	US$3000
偏重研究方向	医学-临床神经学
期刊官网	https://www.journals.elsevier.com/alzheimers-and-dementia/
投稿链接	http://www.alz.org/search/results.asp?q=&Submit=Submit&as_dt=i

质量指标占比

研究类文章占比	OA被引用占比	撤稿占比	出版后修正文章占比
91.39%	57.34%	0.00%	1.41%

预警情况查看说明

时间	预警情况
2024年02月发布的2024版	不在预警名单中
2023年01月发布的2023版	不在预警名单中
2021年12月发布的2021版	不在预警名单中
2020年12月发布的2020版	不在预警名单中

JCR分区 WOS分区等级：Q1区

版本	按学科	分区
WOS期刊SCI分区 WOS期刊SCI分区是指SCI官方（Web of Science）为每个学科内的期刊按照IF数值排序，将期刊按照四等分的方法划分的Q1-Q4等级，Q1代表质量最高，即常说的1区期刊。（2021-2022年最新版）
	CLINICAL NEUROLOGY	Q1

关于2019年中科院分区升级版（试行）

分区表升级版（试行）旨在解决期刊学科体系划分与学科发展以及融合趋势的不相容问题。由于学科交叉在当代科研活动的趋势愈发显著，学科体系构建容易引发争议。为了打破学科体系给期刊评价带来的桎梏，“升级版方案”首先构建了论文层级的主题体系，然后分别计算每篇论文在所属主题的影响力，最后汇总各期刊每篇论文分值，得到“期刊超越指数”，作为分区依据。

分区表升级版（试行）的优势：一是论文层级的主题体系既能体现学科交叉特点，又可以精准揭示期刊载文的多学科性；二是采用“期刊超越指数”替代影响因子指标，解决了影响因子数学性质缺陷对评价结果的干扰。整体而言，分区表升级版（试行）突破了期刊评价中学科体系构建、评价指标选择等瓶颈问题，能够更为全面地揭示学术期刊的影响力，为科研评价“去四唯”提供解决思路。相关研究成果经过国际同行的认可，已经发表在科学计量学领域国际重要期刊。

《2019年中国科学院文献情报中心期刊分区表升级版（试行）》首次将社会科学引文数据库（SSCI）期刊纳入到分区评估中。升级版分区表（试行）设置了包括自然科学和社会科学在内的18个大类学科。基础版和升级版（试行）将过渡共存三年时间，推测在此期间各大高校和科研院所仍可能会以基础版为考核参考标准。提示：中科院分区官方微信公众号“fenqubiao”仅提供基础版数据查询，暂无升级版数据，请注意区分。

中科院分区查看说明

版本	大类学科	小类学科	Top期刊	综述期刊
	医学 1区	CLINICAL NEUROLOGY 临床神经病学 1区	否	是
2021年12月基础版	医学 1区	CLINICAL NEUROLOGY 临床神经病学 1区	否	是
2021年12月升级版	医学 1区	CLINICAL NEUROLOGY 临床神经病学 1区	否	是
2020年12月旧的升级版	医学 1区	CLINICAL NEUROLOGY 临床神经病学 1区	否	是
2022年12月最新升级版	医学 1区	CLINICAL NEUROLOGY 临床神经病学 1区	否	是